Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

8 results
Display

Successful Treatment of Coronary Spasm with Atherosclerosis Rapidly Progressing to Acute Myocardial Infarction in a Young Woman

Han X, Jeong MH, Sim DS, Kim MC, Kim Y, Kim JH, Hong YJ, Ahn Y

Variant angina pectoris (VAP) is a special type of unstable angina with coronary artery spasm as the main pathogenesis, characterized by resting chest pain, and transient ST segment dynamic changes....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Contrast-free (Zero-contrast) TAVR for Severe Aortic Stenosis in Patient with Chronic Kidney Disease

Choi YJ, Ahn CM, Kim DR, Hong GR, Ko YG, Hong MK

Transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) is a minimally invasive interventional procedure that repairs a valve without removing the old,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Valuable Risk Stratification with Hemoglobin Level and Neutrophil to Lymphocyte Ratio in Patients with Non-ST-Elevation Myocardial Infarction Having an Early Invasive Strategy

Jun SJ, Jeong MH, Cho KH, Ahn Y, Kim JH, Cho JG, Chae SC, Kim YJ, Seong IW, Chae JK, Kim HS, for the KAMIR (Korea Acute Myocardial Infarction Registry)-NIH (Korea National Institute of Health) Investigators

OBJECTIVE: The complete blood count is the most widely available laboratory data in the early in-hospital period after acute myocardial infarction. We assessed the clinical utility of the combined use...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardiovascular Disease

Park SD, Bae KH, Choi YK, Jeon JH, Seo JB, Kim N, Kim CY, Kim SW, Lee WK, Kim JG, Lee IK, Lee JH, Park KG

OBJECTIVE: Fibroblast growth factor (FGF) 21 is a recently established therapeutic target for treating metabolic syndromes, which include potential precursors to cardiovascular disease, suggesting a link between FGF21 and atherosclerosis....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)

Jeong IK

In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism

Cho Y, Kang ES

Patients with type 2 diabetes (T2D) have a significantly higher risk of developing cardiovascular diseases such as myocardial infarction, heart failure, and stroke. Current anti-diabetic drugs are highly effective for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
What Do We Get from Recent Statin and CETP Inhibitors Trials?

Kim BJ

Recent clinical trials and meta-analyses have indicated that high-intensive statin treatment lowers low-density lipoprotein cholesterol (LDL-C) levels and reduces the risk of nonfatal cardiovascular (CV) events compared with moderate-intensity statin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors

Lee EY, Yoon KH

Based on evidence from numerous research studies, increased low-density lipoprotein cholesterol (LDL-C) is a clinically important factor for accelerated atherosclerosis and increased cardiovascular risk. The introduction of statin therapy has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr